Journals / Marmara Medical Journal / 2014 / Cilt: 27 - Sayı: 1

-

Sıçanlarda kolite bağlı hasarı nikotin antioksidatif aktivitesi ile hafifletir

Pages
13–20
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: This study demonstrates antioxidant effects of nicotine treatment in the acetic acid-induced colitis model including an increased antioxidant capacity, reduced migration of neutrophils to the inflamed colon and a reduction of membrane damage

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Previous studies have demonstrated a higher incidence of ulcerative colitis in non-smokers.
📊
Key Findings & Data:We investigated the beneficial effects of nicotine treatment on colitis-induced anxiety and oxidative colonic damage on rats.Materials and Methods: Wistar Albino (250-300 g) rats (n=40) were randomly divided into 5 groups as saline-treated colitis group, nicotine pre-treated colitis group, nicotine post-treated colitis group, continuously nicotine-treated colitis group and control group.
💡
Conclusion & Impact:Conclusion: This study demonstrates antioxidant effects of nicotine treatment in the acetic acid-induced colitis model including an increased antioxidant capacity, reduced migration of neutrophils to the inflamed colon and a reduction of membrane damage
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Ulseratif kolit · Anksiyete · Miyeloperoksidaz

Abstract

Objective: Previous studies have demonstrated a higher incidence of ulcerative colitis in non-smokers. We investigated the beneficial effects of nicotine treatment on colitis-induced anxiety and oxidative colonic damage on rats.Materials and Methods: Wistar Albino (250-300 g) rats (n=40) were randomly divided into 5 groups as saline-treated colitis group, nicotine pre-treated colitis group, nicotine post-treated colitis group, continuously nicotine-treated colitis group and control group. Groups received intraperitoneal injections of saline or nicotine (0.1 mg/kg/day) for 15 days prior to and for 3 days following the colitis induction. Malondialdehyde (MDA) and glutathione (GSH) levels, myeloperoxidase (MPO), superoxide dismutase (SOD) and catalase (CAT) activities, histological evaluation and DNA fragmentation were studied in colonic samples. Anxiety levels were evaluated with the hole-board test. Results were evaluated using ANOVA and Mann-Whitney-U tests. Results: The saline-treated colitis group had increased MPO and MDA levels, DNA fragmentation and histological damage scores when compared with the control group. In the nicotinetreated groups MPO and MDA levels and DNA fragmentation were reduced, with lower histologic damage scores. Reduced SOD, CAT and GSH levels were also increased in nicotine-treated groups. Conclusion: This study demonstrates antioxidant effects of nicotine treatment in the acetic acid-induced colitis model including an increased antioxidant capacity, reduced migration of neutrophils to the inflamed colon and a reduction of membrane damage

Özet

Amaç: Epidemiyolojik çalışmalar ülseratif kolitin sigara kullanmayanlarda daha sık görüldüğünü bildirmektedir. Bu çalışmada kolitle oluşan oksidan hasar ve anksiyete üzerine nikotin ön tedavisinin ve/veya kolit sonrası tedavinin olası yararlı etkilerinin araştırılması amaçlanmıştır. Gereç ve Yöntem: Wistar Albino (250-300 g) sıçanlar (n=40), serum fizyolojik (SF) verilen, ön-tedavili, tedavili ve ön-tedavi+ tedavili kolit grubu ve kontrol grubu olmak üzere beşe ayrıldı. Kolit öncesi 15 gün ve kolit sonrasında 3 gün sıçanlara intraperitoneal SF ya da nikotin (0,1 mg/kg/gün) uygulandı. Kolon örneklerinde oksidan hasarı belirlemek için malondialdehid (MDA), miyeloperoksidaz (MPO) aktivitesi, glutatyon (GSH), süperoksit dismutaz (SOD), katalaz ve DNA fragmantasyonu ölçümleri ile histolojik skorlama yapıldı. Delikli kutu testi ile anksiyete seviyeleri belirlendi. Sonuçlar ANOVA ve Mann Whitney U testi ile analiz edildi. Bulgular: Kolitte artan anksiyetenin nikotin ile değişmediği gözlendi. SF verilen kolit grubunda kolon MPO ve MDA düzeyleri ile DNA fragmantasyonunun ve hasar skorunun kontrol grubuna kıyasla arttığı, nikotin verilen tüm kolit gruplarında ise bu hasar göstergelerinin anlamlı şekilde düştüğü gözlendi. Histolojik doku hasarı skorunun nikotin uygulanan kolit grubunda daha az olduğu gözlendi. SOD, katalaz ve GSH düzeylerindeki azalmanın nikotin tedavisiyle anlamlı şekilde arttığı gözlendi. Sonuç: Çalışmada asetik asitle oluşturulan kolit modelinde, nikotin tedavisinin doku antioksidan kapasitesini arttırarak, inflamasyon sonucu nötrofil göçünü ve membran hasarını azaltarak antioksidan etki oluşturduğu gösterildi.

🔖

Cite This Article

OZDEMİR, Z. N., TAZEGUL, G., KURU, P., BILGIN, S., MENTESE, S. T., ERZİK, C., ŞİRVANCI, S., YEGEN, B. C. (2014). -. Marmara Medical Journal, Cilt: 27 - Sayı: 1, 13–20. https://ajindex.com/articles/283936

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: Up or down? World J Gastroenterol 2006;12:6102–8
  2. Maritz GS, Mutemwa M. Tobacco smoking: patterns, health consequences for adults, and the long-term health of the offspring. Glob J Health Sci 2012; 30;4:62-75
  3. Harries AD, Baird A, and Rhodes J. Non-smoking: A feature of ulcerative colitis. Br Med J (Clin Res Ed). 1982; 284(6317):706. doi: 10.1136/bmj.284.6317.706 4. Koutroubakis I, Manousos ON, Menuwissen SG, Pena AS. Environmental risk factors in inflammatory bowel disease. Hepatogastroenterology 1996; 43: 381–93
  4. Graff LA, Walker JR, Bernstein CN. It’s not just about the gut: managing depression and anxiety in inflammatory bowel disease. Prac Gastroenterol 2010;34:11–25
  5. GilbertDG, Robinson,JH, Chamberlin CL, Spielberger CD. Effects of smoking/nicotine on anxiety, heart rate, and lateralization of EEG during a stressful movie. Psychophysiology1989;26:311-20. doi: 10.1111/j.1469-8986.1989.tb01924.x 7. Guslandi M, Tittobello A. Outcome of ulcerative colitis after treatment with transdermal nicotine. Eur J Gastroenterol Hepatol 1998;10:513- 5. doi: 10.1097/00042737-199806000-00014 8. Sandborn W, Tremaine W, Leighton J, et al. Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study. Aliment Pharmacol Ther 1997;11:663-71. doi: 10.1046/j.1365-2036.1997.00208.x 9. Sandborn WJ, Tremaine WJ, Offord KP, et al.Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997;126; 364-71. doi: 10.7326/0003-4819-126-5-199703010-00004 10. Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J. Inflammatory intermediates in inflammatory bowel disease. Int J Colorectal Dis 1989;4:75–90
  6. Brown SJ, Mayer L. The immune response in inflammatory bowel disease. Am J Gastroenterol 2007;102:2058-69. doi: 10.1111/ j.1572- 0241.2007.01343.x 12. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000;51:289-98. doi: 10.1146/annurev.med.51.1.289 13. Saareks V, Riutta A, Mucha I, Alanko J, Vapaatalo H. Nicotine and cotinine modulate eicosanoid production in human leukocytes and platelet rich plasma. Eur J Pharmacol 1993; 248: 345–9. doi: dx.doi. org/10.1016/0926-6917(93)90012-F 14. Zijlstra FJ, Scrivastava ED, Rhodes M, et al. Effect of nicotine on rectal mucus and mucosa